AI brings savings to clinical trials: study
Artificial intelligence isn't just speeding up early-stage drug development, it's starting to unlock millions of dollars' worth of new efficiencies in clinical trials on cancer treatments, research shared first with Axios shows.Why it matters: AI-powered tools could shave months off time-consuming processes like recruiting and enrolling patients, monitoring results and interpreting data.That could free up resources for more clinical studies and possibly lower the high failure rate for new drugs. What they found: A new Tufts Center for the Study of Drug Development analysis found AI agents can accelerate clinical development of cancer drugs by approximately 10 weeks and reduce direct operating costs by as much as $5.6 million in late-stage trials.
Reported by 1 outlet — Axios. See all sources ↓
Artificial intelligence isn't just speeding up early-stage drug development, it's starting to unlock millions of dollars' worth of new efficiencies in clinical trials on cancer treatments, research shared first with Axios shows.Why it matters: AI-powered tools could shave months off time-consuming processes like recruiting and enrolling patients, monitoring results and interpreting data.That could free up resources for more clinical studies and possibly lower the high failure rate for new drugs. What they found: A new Tufts Center for the Study of Drug Development analysis found AI agents can accelerate clinical development of cancer drugs by approximately 10 weeks and reduce direct operating costs by as much as $5.6 million in late-stage trials. The efficiencies increase with the number of tumors a drug can target: An experimental treatment with 50 active uses could see net benefits of as much as $565 million, Tufts found. Tufts applied a clinical monitoring agent from Medable, which provides a platform to support clinical trials, to an unspecified oncology drug development program in phase 2 and 3 trials.What they're saying: Ken Getz, the Tufts center's executive director, said deploying the agent led to new efficiencies, such as reducing the number of on-site visits, accelerating enrollment in the trial and locking in the data.
Read the full report at Axios ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- Artificial intelligence isn't just speeding up early-stage drug development, it's starting to unlock millions of dollars' worth of new efficiencies in clinical trials on cancer treatments, research shared first with Axios shows.Why it matters: AI-powered tools could shave months off time-consuming processes like recruiting and enrolling patients, monitoring results and interpreting data.That could free up resources for more clinical studies and possibly lower the high failure rate for new drugs. What they found: A new Tufts Center for the Study of Drug Development analysis found AI agents can accelerate clinical development of cancer drugs by approximately 10 weeks and reduce direct operating costs by as much as $5.6 million in late-stage trials.
- How widely is it covered?
- 1 outlet, average source rating 7.0/10.
- When was it last updated?
- 14m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
AI brings savings to clinical trials: study
Sources1TypeCoverageAxios